Last reviewed · How we verify
Erythropoietin alpha
Erythropoietin alpha stimulates erythropoiesis by binding to the erythropoietin receptor.
Erythropoietin alpha stimulates erythropoiesis by binding to the erythropoietin receptor. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.
At a glance
| Generic name | Erythropoietin alpha |
|---|---|
| Also known as | Erythropoietin alpha (Epogen) |
| Sponsor | Mathew S. Maurer |
| Drug class | erythropoiesis-stimulating agent |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This binding activates the JAK2/STAT5 signaling pathway, leading to increased production of red blood cells. Erythropoietin alpha is a recombinant form of the naturally occurring hormone erythropoietin, which is produced by the kidneys in response to hypoxia.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia associated with chemotherapy
Common side effects
- Thromboembolism
- Hypertension
- Headache
- Nausea
- Fatigue
Key clinical trials
- High Dose of Erythropoietin Analogue After Cardiac Arrest (PHASE3)
- Long Term Beta Thalassemia Treatment: Findings From The Extension Period (PHASE2)
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (PHASE3)
- Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child (NA)
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome (PHASE2)
- A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (PHASE3)
- The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (PHASE2)
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erythropoietin alpha CI brief — competitive landscape report
- Erythropoietin alpha updates RSS · CI watch RSS
- Mathew S. Maurer portfolio CI